Recce Pharmaceuticals Ltd. · ASX:RCE

Recce Pharmaceuticals — Investor Presentation (December 2024)

36 slides from Recce Pharmaceuticals's investor presentation, December 2024

  1. Slide 1: RCE Corporate Presentation

    Slide 1: RCE Corporate Presentation

    RCE Corporate Presentation ASX:RCE | FSE:R9Q December XXXX 2024

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer DISCLAIMER This pre sen tation has been pre pared by Recce Pharmaceuticals Ltd (the “Co mp any”). It do es not purpo rt to con tain all the info rmation tha t a prospective investo r may requir e in conne ction with any potential investment in the Company. Yo u shou ld n ot treat the cont

  3. Slide 3: About Recce Pharmaceuticals Ltd

    Slide 3: About Recce Pharmaceuticals Ltd

    About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a new class of Synthetic Anti-Infectives • Australian clinical-stage biotech company, with a United States presence • Qualified Infectious Disease Product designation – 10 years of market exclusivity plus fa

  4. Slide 4: Board and Management Structure

    Slide 4: Board and Management Structure

    Board and Management Structure Dr John Prendergast – Chairman Michele Dilizia – Executive Director & Chief Scientific BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) Officer BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM US-based, current Chairman and Co-founder of Palatin Tech nologies,

  5. Slide 5: Company Overview

    Slide 5: Company Overview

    Company Overview Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives Capital Structure – December 2024 RCE Share Price and Volume Chart – 12 Months (price shown in AUD) ASX & FSE Code RCE, R9Q 2,500,000 $0.80 Share Price AUD $0.4600 $0.70

  6. Slide 6: The Need for a New Class of Antibiotics: Synthetic Anti-Infectives

    Slide 6: The Need for a New Class of Antibiotics: Synthetic Anti-Infectives

    The Need for a New Class of Antibiotics: Synthetic Anti-Infectives On-track to be the only global clinical stage company whose drug is shown to be efficacious against the full suite of ESKAPE pathogens. • NO pre-formed natural superbugs. • Very broad-spectrum coverage of bacteria with no signs of re

  7. Slide 7: Strong Pipeline

    Slide 7: Strong Pipeline

    Strong Pipeline Over Various Indications and Upcoming Inflection Points 6

  8. Slide 8: Sepsis – it's a big problem!

    Slide 8: Sepsis – it's a big problem!

    Sepsis – it’s a big problem! Sepsis is a life-threatening inflammatory response to infection that has spread in the body. Is the most expensive condition to 48.9 Cases of sepsis treat in the last 8 years5. Double the average cost per stay across all other million recorded worldwide1 conditions5. Kil

  9. Slide 9: Sepsis Patient Journey

    Slide 9: Sepsis Patient Journey

    Sepsis Patient Journey Patient Presents at the Hospital Current Treatment Paradigm • Mortality from sepsis increases by as much as 8% for • Introducing broad-spectrum antibiotic (s) every hour that treatment is delayed. • Running antibiograms • Cost of sepsis care for inpatient admissions and skille

  10. Slide 10: Independent Study Undertaken on R327 MoA

    Slide 10: Independent Study Undertaken on R327 MoA

    Independent Study Undertaken on R327 MoA1 By Leading Experts in Bacterial MoA Analysis Stage 1 Stage 2 • Novel mechanism which targets rapid access to and shut down of bacterial energy production (ATP) which results in bacterial death of both active and resting bacteria. R327 arrests cell growth R32

  11. Slide 11: RECCE Activity Against Escherichia coli

    Slide 11: RECCE Activity Against Escherichia coli

    RECCE® 327 Activity Against Escherichia coli • E. coli grows fast. Eukaryotic cells healthy Without R327 R327 (3,000 ppm) and not affected. • R327 at 3,000 ppm shown to be highly effective against E. coli without affecting growing, healthy eukaryotic cells. • R327 rapidly and irreversibly shuts down

  12. Slide 12: RECCE Activity Against Staphylococcus aureus

    Slide 12: RECCE Activity Against Staphylococcus aureus

    RECCE® 327 Activity Against Staphylococcus aureus • S. aureus bacterial growth slower than E. coli, not Without R327 R327 (2,300 ppm) affecting eukaryotic cells. • R327 at 2,300 ppm shows to be highly effective against S. aureus without affecting growing, healthy eukaryotic cells. • R327 rapidly and

  13. Slide 13: RECCE Maintains Activity

    Slide 13: RECCE Maintains Activity

    RECCE® 327 Maintains Activity Number of repeats before displaying loss of antibiotic activity Bacteria* 2 4 6 8 10 12 14 16 18 20 22 24 25 Escherichia coli 25 repeats at time of discovery was sufficient for PCT patent applications, with no sign of resistance. Pseudomonas aeruginosa Staphylococcus au

  14. Slide 14: Bactericidal Effect of RECCE on ESKAPE Pathogens

    Slide 14: Bactericidal Effect of RECCE on ESKAPE Pathogens

    Bactericidal Effect of RECCE® 327 on ESKAPE Pathogens E. faecium ATCC S. aureus ATCC K. pneumoniae ATCC 19434 29213 43816 A. baumannii ATCC 17978 P. aeruginosa ATCC 27853 Enterobacter cloacae ATCC 13047 • Average time-kill curv es of R327 at various conc ent rat ions against strains of ESKAPE pathog

  15. Slide 15: R327 Faster Acting Than Existing Antibiotics

    Slide 15: R327 Faster Acting Than Existing Antibiotics

    R327 Faster Acting Than Existing Antibiotics No Prolonged Exposure Needed • R327 kills pathogenic bacteria at a faster rate. • R327 designed to work faster than all existing antibiotics, reinforced by MoA work undertaken by experts in their field. “R327 kills bacteria in conditions where other antib

  16. Slide 16: RECCE Summary Results – Phase I – Complete

    Slide 16: RECCE Summary Results – Phase I – Complete

    RECCE® 327 Summary Results – Phase I – Complete Double-blind, Placebo-controlled, Single Ascending-dose, Safety and Pharmacokinetic Study in Healthy Participants ✓ Safe and well tolerated at doses up to 6,000mg given as a 1-hour intravenous infusion; ✓ No Serious Adverse Events; – All AE’s mild or m

  17. Slide 17: RECCE Concentrates Safely in the Urine

    Slide 17: RECCE Concentrates Safely in the Urine

    RECCE® 327 Concentrates Safely in the Urine Concentration of R327 Ratio Urine/Plasma in Urine Compared to Plasma 16x 17x 14x 9x In over 60 21x healthy subjects 16x – R327 primary route of elimination appears to be through – Opportunities for therapeutic in array of UTIs (uncomplicated the kidney to

  18. Slide 18: RECCE Kills Quickly in the Urine

    Slide 18: RECCE Kills Quickly in the Urine

    RECCE® 327 Kills Quickly in the Urine E. coli ATCC 25922 Treated with RECCE® 327 in Urine • R327 in the presence of human urine was able to 10.00 have a fast (near minutes) effect against E. coli 9.00 and irreversible Viable Bacteria (log CFU/ml) 8.00 • Bacteria could not be revived post-treatment •

  19. Slide 19: Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial

    Slide 19: Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial

    Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial R327 has achieved multiple ‘fast infusion’ time stamps in line with intended future regulatory submissions • Assessing R327 at faster administration rates (<1 hour) 15 minutes • Trial aimed at positioning R327 as first patient presentation 20 mi

  20. Slide 20: Topical Clinical Programs

    Slide 20: Topical Clinical Programs

    Topical Clinical Programs Phase I/II Clinical Trial – Treatment of Burn Wound Infections • Stage 1 Complete • Patients treated with R327 showed good indications of safety and tolerability • No serious adverse events reported among patients • Clinical investigators are preparing a new protocol of nex

  21. Slide 21: Phase I/II DFI Clinical Trial – Achieved Primary Endpoints

    Slide 21: Phase I/II DFI Clinical Trial – Achieved Primary Endpoints

    Phase I/II DFI Clinical Trial – Achieved Primary Endpoints • Patients recruited had mild skin and soft tissue DFI including multidrug-resistant Gram-positive and Gram-negative pathogens • Study met all primary end points • R327 well-tolerated in all patients; DFI’s resolved/cured *Patient was on sys

  22. Slide 22: Phase II ABSSSI Clinical Trial – Dosing Halfway Complete

    Slide 22: Phase II ABSSSI Clinical Trial – Dosing Halfway Complete

    Phase II ABSSSI Clinical Trial – Dosing Halfway Complete Efficacy Data and Safety Approval Received NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES • Non-Data Safety Monitoring Board unanimously agree R327G is safe and well-tolerated in patients – demonstrating highly encour

  23. Slide 23: Patient Case Study – TGA Special Access Scheme Category A

    Slide 23: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 0 Day 0 Day 1 Day 30 Day 0 – Recce treatment Day 0 – Recce treatment Day 0 – Recce treatment Day 1 – Recce treatment Day 30 – Recce treatment Pre-treatment infection First Recce gel applied Gel application complete Post treatment Po

  24. Slide 24: Patient Case Study – TGA Special Access Scheme Category A

    Slide 24: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 7 Day 10 Day 14 Day 0 – Recce treatment Day 7 – Recce treatment Day 10 – Recce treatment Day 14 – Recce treatment Significant bacterial infection Initial redness and swelling No signs of infection, no signs of pus Wound impr

  25. Slide 25: Patient Case Study – TGA Special Access Scheme Category A

    Slide 25: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 7 Day 14 Day 21 Day 0 – Pre-treatment wound swab Day 7 – Recce treatment Day 14 – Recce treatment Day 21 – Recce treatment Growing culture of Gram-positive and Initial redness and swelling of the No signs of bacterial growth

  26. Slide 26: Patient Case Study – TGA Special Access Scheme Category A

    Slide 26: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 3 Day 7 Significant bacterial infection Redness and swelling Left femoral Day 0 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment Significant bacterial infection, redness and Initial redness and swelling minimi

  27. Slide 27: Patient Case Study – TGA Special Access Scheme Category A

    Slide 27: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 3 Day 7 Day 1 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment Osteomyelitis (serious infection of the bone), signs of Wound drying up with infection clearing, toe Wound completely dried up, no signs of biofil

  28. Slide 28: Patient Case Study – Special Access Scheme Category A

    Slide 28: Patient Case Study – Special Access Scheme Category A

    Patient Case Study – Special Access Scheme Category A Pre-Treatment Day 5 NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES Significant bacterial infection Day 0 – Pre-treatment Day 5 – Recce treatment Significant bacterial infection – septic ankle arthritis, peri- The dischar

  29. Slide 29: RECCE Activity Against Multiple Bacterial Infections

    Slide 29: RECCE Activity Against Multiple Bacterial Infections

    RECCE® 327 Activity Against Multiple Bacterial Infections Recce’s Anti-Infective Research (AIR) Unit – Located within Murdoch Children’s Research Institute, one of the top three children’s research institutes worldwide – Ongoing pre-clinical programs, exploring new research development opportunities

  30. Slide 30: Robust Worldwide Intellectual Property Portfolio

    Slide 30: Robust Worldwide Intellectual Property Portfolio

    Robust Worldwide Intellectual Property Portfolio Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets. Patent Patent Patent Patent Expiry Expiry Expiry Expiry Filed Family 1 Family 2 Family 3 Family 4 Family 1 group relates to the Company’s Unique an

  31. Slide 31: Manufacturing & Scalability

    Slide 31: Manufacturing & Scalability

    Manufacturing & Scalability Manufacturing facility in Sydney’s Macquarie Park • Raw materials plentiful and cheap – few $/Kg • No expensive waste – 99.9% product yield • Automated manufacture process – completing 5,000 doses a week under GMP • This in-house pilot facility provides clear benefits in

  32. Slide 32: Strategic Opportunity in South-East Asia to Accelerate Clinical Program

    Slide 32: Strategic Opportunity in South-East Asia to Accelerate Clinical Program

    Strategic Opportunity in South-East Asia to Accelerate Clinical Program Phase III Registrational Clinical Trial in Indonesia Topical Gel • Human Research Ethics Committee approval received for Registrational Phase 3 Clinical Trial for RECCE 327 Topical Gel • BPOM approval expected to imminently foll

  33. Slide 33: Department of Defense R&D Efforts

    Slide 33: Department of Defense R&D Efforts

    Department of Defense R&D Efforts • Recce awarded funding for FY23 Military Burn Research Program under the U.S. Army Medical Research and Development Command, via a Congressionally Directed Medical Research Program Award. • Proposal Title: A Novel, Synthetic Anti-infective Drug Candidate, R327, for

  34. Slide 34: RECCE – Global Recognition

    Slide 34: RECCE – Global Recognition

    RECCE® 327 – Global Recognition R327 added to World Health Organization’s List of Antibacterial Products in Clinical Development • Global recognition by the World Health Organization (WHO) – inclusion underscores significance of R327 in combating antimicrobial resistance. • Unique Mechanism of Actio

  35. Slide 35: Summary – Significant Opportunities Ahead

    Slide 35: Summary – Significant Opportunities Ahead

    Summary – Significant Opportunities Ahead Proprietary first-in-class, broad-spectrum anti-infectives against bacteria, protected by Composition of Matter Patent. Fast development plans targeting: Sepsis, UTI/Urosepsis, Burn Wounds and Acute Bacterial Skin and Skin Structure Infections (ABSSSI), incl

  36. Slide 36: Thank you

    Slide 36: Thank you

    Thank you @0@ = recce.com.au

Source: Internet Archive copy of recce.com.au

More decks from Recce Pharmaceuticals Ltd.

All 45 Recce Pharmaceuticals decks